Physician profile
Thaddeus C Rogozinski
NPI 1609827815
$911.92
in general payments reported to CMS, 2019-2025
12 companies · $107 in 2025
The $107 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $83.65 · 2021: $34.68 · 2022: $19.73 · 2023: $302 · 2024: $56.03 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $169.27 | 2019-2023 | Bridion |
| Boston Scientific Corporation | $157.30 | 2023 | Spyglass |
| Amgen INC. | $132.97 | 2019 | |
| Mallinckrodt Hospital Products INC. | $83.65 | 2020 | |
| Davol INC. | $78.95 | 2025 | Phasix Mesh |
| Integra Lifesciences Corporation | $74.85 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Mallinckrodt Enterprises LLC | $53.48 | 2019 | |
| Olympus America INC. | $45.55 | 2023-2024 | Soltive, Olympus |
| Pacira Pharmaceuticals Incorporated | $34.68 | 2021 | |
| Heron Therapeutics, INC. | $33.21 | 2024 | Aponvie |
| Avita Medical Americas, LLC | $28.28 | 2025 | Cohealyx, Recell, Permeaderm |
| Kci USA, INC. | $19.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddeus Rogozinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.